Omnicom recently reorganized its health agencies under the Omnicom Health Group umbrella.
U.S. Keytruda sales miss mark; the CDC warns parents to try therapy before drugs for children with ADHD; FDA panel recommends training for opioid prescribers
Did your agency report record growth in 2015? Tell us why when you fill out the A-to-Z questionnaire for MM&M's upcoming agency issue. The deadline is Friday.
The FDA issues warning for certain antipsychotics; Shkreli may face more securities charges; Genentech and Stand Up to Cancer launch campaign
IMS and Quintiles to merge and create $17 billion firm; Biogen spins off hemophilia company; Google partners with the National Health Service
Express Scripts to roll out pricing response program; the FDA approves new Parkinson's disease treatment; Regeneron's plaque psoriasis drug hits endpoint
Harvoni and Sovaldi growth begins to slow; drugmakers spend billions to buy developers of cancer therapies; Valeant discloses new investigations
The drugmaker said it plans to increase its investment in DTC for the immuno-oncology drug.
Pfizer settles rebate suit; Sanofi moves to acquire Medivation; AstraZeneca sells US rights to gout drug
The Senate committee on Aging said Valeant's missteps go beyond price hikes and that its business model is fundamentally to blame.